Your browser doesn't support javascript.
Broad neutralization of SARS-related viruses by human monoclonal antibodies.
Wec, Anna Z; Wrapp, Daniel; Herbert, Andrew S; Maurer, Daniel P; Haslwanter, Denise; Sakharkar, Mrunal; Jangra, Rohit K; Dieterle, M Eugenia; Lilov, Asparouh; Huang, Deli; Tse, Longping V; Johnson, Nicole V; Hsieh, Ching-Lin; Wang, Nianshuang; Nett, Juergen H; Champney, Elizabeth; Burnina, Irina; Brown, Michael; Lin, Shu; Sinclair, Melanie; Johnson, Carl; Pudi, Sarat; Bortz, Robert; Wirchnianski, Ariel S; Laudermilch, Ethan; Florez, Catalina; Fels, J Maximilian; O'Brien, Cecilia M; Graham, Barney S; Nemazee, David; Burton, Dennis R; Baric, Ralph S; Voss, James E; Chandran, Kartik; Dye, John M; McLellan, Jason S; Walker, Laura M.
  • Wec AZ; Adimab LLC, Lebanon, NH 03766, USA.
  • Wrapp D; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712, USA.
  • Herbert AS; U.S. Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
  • Maurer DP; Adimab LLC, Lebanon, NH 03766, USA.
  • Haslwanter D; Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, NY 10462, USA.
  • Sakharkar M; Adimab LLC, Lebanon, NH 03766, USA.
  • Jangra RK; Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, NY 10462, USA.
  • Dieterle ME; Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, NY 10462, USA.
  • Lilov A; Adimab LLC, Lebanon, NH 03766, USA.
  • Huang D; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
  • Tse LV; Department of Epidemiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
  • Johnson NV; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712, USA.
  • Hsieh CL; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712, USA.
  • Wang N; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712, USA.
  • Nett JH; Adimab LLC, Lebanon, NH 03766, USA.
  • Champney E; Adimab LLC, Lebanon, NH 03766, USA.
  • Burnina I; Adimab LLC, Lebanon, NH 03766, USA.
  • Brown M; Adimab LLC, Lebanon, NH 03766, USA.
  • Lin S; Adimab LLC, Lebanon, NH 03766, USA.
  • Sinclair M; Adimab LLC, Lebanon, NH 03766, USA.
  • Johnson C; Adimab LLC, Lebanon, NH 03766, USA.
  • Pudi S; Adimab LLC, Lebanon, NH 03766, USA.
  • Bortz R; Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, NY 10462, USA.
  • Wirchnianski AS; Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, NY 10462, USA.
  • Laudermilch E; Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, NY 10462, USA.
  • Florez C; Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, NY 10462, USA.
  • Fels JM; Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, NY 10462, USA.
  • O'Brien CM; U.S. Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
  • Graham BS; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Nemazee D; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
  • Burton DR; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
  • Baric RS; IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.
  • Voss JE; Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA 92037, USA.
  • Chandran K; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Cambridge, MA 02139, USA.
  • Dye JM; Department of Epidemiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
  • McLellan JS; Departments of Microbiology and Immunology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
  • Walker LM; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Science ; 369(6504): 731-736, 2020 08 07.
Article in English | MEDLINE | ID: covidwho-599033
ABSTRACT
Broadly protective vaccines against known and preemergent human coronaviruses (HCoVs) are urgently needed. To gain a deeper understanding of cross-neutralizing antibody responses, we mined the memory B cell repertoire of a convalescent severe acute respiratory syndrome (SARS) donor and identified 200 SARS coronavirus 2 (SARS-CoV-2) binding antibodies that target multiple conserved sites on the spike (S) protein. A large proportion of the non-neutralizing antibodies display high levels of somatic hypermutation and cross-react with circulating HCoVs, suggesting recall of preexisting memory B cells elicited by prior HCoV infections. Several antibodies potently cross-neutralize SARS-CoV, SARS-CoV-2, and the bat SARS-like virus WIV1 by blocking receptor attachment and inducing S1 shedding. These antibodies represent promising candidates for therapeutic intervention and reveal a target for the rational design of pan-sarbecovirus vaccines.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Severe acute respiratory syndrome-related coronavirus / Spike Glycoprotein, Coronavirus / Betacoronavirus / Broadly Neutralizing Antibodies / Antibodies, Monoclonal / Antibodies, Viral Type of study: Randomized controlled trials Topics: Vaccines Limits: Adult / Aged / Female / Humans / Male / Middle aged / Young adult Language: English Journal: Science Year: 2020 Document Type: Article Affiliation country: Science.abc7424

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Severe acute respiratory syndrome-related coronavirus / Spike Glycoprotein, Coronavirus / Betacoronavirus / Broadly Neutralizing Antibodies / Antibodies, Monoclonal / Antibodies, Viral Type of study: Randomized controlled trials Topics: Vaccines Limits: Adult / Aged / Female / Humans / Male / Middle aged / Young adult Language: English Journal: Science Year: 2020 Document Type: Article Affiliation country: Science.abc7424